ASCO 2021: HER2CLIMB update shows benefits of adding tucatinib to trastuzumab & capecitabine are maintained in metastatic breast cancer June 4, 2021
Pyrotinib plus capecitabine vs lapatinib plus capecitabine for the treatment of HER2+ metastatic breast cancer February 17, 2021